title: Erythroblastopenia in two patients after splenectomy and polychemotherapy.
abstract: Acquired erythroblastopenia is a rare disorder of the hematopoietic system associated with viral infections, autoimmune diseases, and drugs. We report on two patients who became anemic due to maturation-arrest at the proerythroblast level, without alterations of white blood cell or platelet counts. Both patients had been splenectomized and had undergone chemotherapy for nephroblastoma or Hodgkin's disease, respectively, at the same pediatric oncology unit. Erythropoietin levels were elevated in both patients. Antibodies against specific viruses, particularly parvovirus B 19, could not be detected in patient sera. Both patients responded to infusions of 7 S immunoglobulin with a rapid increase of the reticulocyte counts. In both cases, complete clinical remission was observed after a duration of 5 months. Heat-inactivated serum obtained during the acute phase and after remission as well was found to be inhibitory for normal bone marrow granulocyte and erythrocyte progenitor growth in vitro. The simultaneous appearance of this rare disorder in two otherwise unrelated patients treated at the same unit prompts speculations about a viral etiology.
authors.affiliation: Klinikum Rudolf Virchow, Kaiserin Auguste Victoria Haus, Berlin, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Domeyer
authors.forename: U
authors.initials: U
authors.lastname: Schulte-Overberg
authors.forename: I
authors.initials: I
authors.lastname: Boll
authors.forename: E
authors.initials: E
authors.lastname: Baumgarten
authors.forename: C
authors.initials: C
authors.lastname: Bührer
authors.forename: R
authors.initials: R
authors.lastname: Fengler
authors.forename: G
authors.initials: G
authors.lastname: Henze
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D003428:Cross Infection; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003609:Dactinomycin / Q000008:administration & dosage / Q000009:adverse effects; D004198:Disease Susceptibility / Q000209:etiology; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004900:Erythroblasts; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000601:surgery; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy / Q000601:surgery; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D013156:Splenectomy / Q000009:adverse effects*; D013160:Splenic Neoplasms / Q000188:drug therapy / Q000601:surgery; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D014777:Virus Diseases
chemical_list: D007074:Immunoglobulin G; D003609:Dactinomycin; D011344:Procarbazine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone